NFE2L2 and non-small cell lung carcinoma: Disappointingly, the KEAPSAKE trial, a Phase 2, randomized, multicenter, double-blind study of CB-839 with pembrolizumab and chemotherapy versus placebo with pembrolizumab and chemotherapy for first line treatment of metastatic KEAP1/NRF2-mutant NSCLC was terminated early due to lack of clinical efficacy.